Testosterone replacement therapy (TRT) has moved from urology offices into mainstream telehealth, but the core pharmacology has not changed in decades. The most common injectable formulation in the United States remains testosterone cypionate: a long-chain ester suspended in oil, typically at 200 mg/mL, injected intramuscularly or subcutaneously on a weekly or biweekly schedule.

Understanding cypionate TRT requires separating three questions that often get conflated: whether a patient has biochemically confirmed hypogonadism, whether treatment is appropriate given symptoms and comorbidities, and how to dose and monitor once therapy starts. This article addresses all three from an educational perspective, grounded in the 2018 Endocrine Society clinical practice guideline and the pharmacokinetics that drive real-world protocols.

What hypogonadism means clinically

Hypogonadism is defined by consistently low serum testosterone combined with symptoms attributable to androgen deficiency. The Endocrine Society recommends diagnosing testosterone deficiency only in men with unequivocally low morning total testosterone on at least two separate days, confirmed by reliable assays, in the setting of relevant symptoms.

Common symptoms include reduced libido, erectile dysfunction, fatigue, depressed mood, decreased muscle mass, increased adiposity, and loss of motivation. These symptoms are nonspecific; depression, sleep apnea, thyroid disease, and medication side effects can mimic low testosterone. That is why the biochemical confirmation matters and why a single afternoon testosterone level is insufficient.

Reference ranges vary by laboratory, but total testosterone below roughly 300 ng/dL on repeated morning measurements in symptomatic men typically triggers further evaluation. Free testosterone may be measured when SHBG is abnormal, but total testosterone remains the primary screening metric in most guidelines.

Why cypionate dominates injectable TRT

Testosterone is not bioavailable orally due to first-pass hepatic metabolism. Injectable esters solve this by creating a depot in muscle or subcutaneous tissue from which testosterone is slowly cleaved from its ester bond and released into circulation.

Cypionate has an eight-carbon ester side chain, intermediate in length between propionate (short, frequent injections) and undecanoate (very long, less common in US practice). After intramuscular injection, testosterone cypionate produces a peak serum concentration within 24 to 72 hours, then a gradual decline over approximately 7 to 14 days depending on dose and injection site.

Enanthate is pharmacokinetically nearly identical and interchangeable in most protocols. Cypionate prevails in US compounding and pharmacy formularies largely due to historical availability and payer familiarity. The standard wholesale vial is 200 mg/mL in a 10 mL multi-dose vial, which is the concentration virtually every telehealth TRT platform specifies.

Dosing philosophies: one size does not fit

There is no FDA-approved single dose for TRT because target testosterone ranges and patient response vary. Typical starting regimens for cypionate fall between 100 mg and 200 mg per week, often expressed as:

The peak-trough problem is real. A man injecting 200 mg every two weeks may spend several days at supraphysiologic levels followed by a week approaching hypogonadal range before the next injection. More frequent smaller doses (weekly or twice-weekly) produce steadier serum testosterone, which many clinicians and patients prefer for mood stability and symptom consistency.

Subcutaneous injection into abdominal fat has gained acceptance as an alternative to intramuscular gluteal or thigh injection, with studies showing comparable absorption and patient preference for the less painful technique. Needle gauge, injection depth, and rotation sites remain part of patient education.

What treatment aims to achieve

TRT is not about maximizing testosterone. The therapeutic goal is restoring mid-normal physiologic range (commonly cited as roughly 450 to 700 ng/dL total testosterone, laboratory-dependent) while relieving symptoms and avoiding adverse effects.

Symptom improvement often begins within 3 to 6 weeks for libido and mood, 6 to 12 weeks for body composition changes, and 3 to 6 months for full hematologic and metabolic stabilization. Patients who expect immediate gym transformation in week one are misaligned with physiology.

Monitoring: the non-negotiable labs

The Endocrine Society recommends monitoring at 3 to 6 months after initiation, then annually in stable patients, with more frequent checks during dose titration. Core surveillance includes:

Hematocrit and hemoglobin

Testosterone stimulates erythropoiesis. Elevated hematocrit (polycythemia) is the most common dose-limiting adverse effect of TRT, increasing thrombotic risk if unchecked. Hematocrit above 54% typically prompts dose reduction or therapeutic phlebotomy per guideline recommendations. This is why TRT without periodic blood work is not acceptable medical practice.

PSA and prostate examination

TRT does not cause prostate cancer, but it can accelerate growth in an existing subclinical malignancy. Baseline PSA, digital rectal exam where indicated, and follow-up PSA at 3 to 12 months are standard. A PSA rise greater than 1.4 ng/mL within 12 months warrants urology referral.

Estradiol

Aromatization of testosterone to estradiol is normal. Some men on TRT develop gynecomastia or emotional lability at higher estradiol levels. Routine estradiol monitoring is debated in guidelines but widely practiced in telehealth TRT. Management ranges from dose adjustment to aromatase inhibitor adjunct (anastrozole) in selective cases, which is itself a prescribing decision with bone-density implications if over-suppressed.

Lipids, liver function, and fertility markers

Testosterone can lower HDL cholesterol modestly. Hepatotoxicity is not expected with injectable testosterone (unlike oral methylated androgens). Men who desire future fertility must understand that exogenous testosterone suppresses intratesticular testosterone and spermatogenesis, often severely. TRT is contraceptive for most men while on therapy. Fertility-preserving alternatives like enclomiphene or hCG are discussed in separate protocols.

Contraindications and caution flags

Guidelines recommend against testosterone therapy in men with:

Cardiovascular risk has been extensively debated. The TRAVERSE trial (2023) in men with hypogonadism and elevated cardiovascular risk found that testosterone therapy was noninferior to placebo for major adverse cardiac events over a median 33 months, though erythrocytosis and atrial fibrillation were more common in the testosterone group. This shifted but did not eliminate the conversation about individualized risk assessment.

Compounded vs. commercial cypionate

Testosterone cypionate is commercially available as Depo-Testosterone and generic equivalents. Compounded versions from 503A pharmacies use the same active ingredient at the same standard concentration (200 mg/mL) but may differ in carrier oil (cottonseed, grapeseed, MCT), which can matter for patients with seed-oil allergies or injection pain.

Compounded testosterone is not FDA-approved as a finished product, but testosterone cypionate itself is a well-characterized USP ingredient. Patients should receive medication from licensed pharmacies with potency and sterility testing rather than unregulated sources.

The telehealth TRT model

Modern TRT platforms follow a repeatable arc: asynchronous or synchronous intake, morning total testosterone and CBC labs, provider review, prescription of cypionate with injection supplies, home injection teaching, and scheduled follow-up labs at 6 to 12 weeks then quarterly or semiannually.

What separates competent platforms from testosterone mills is adherence to two-morning-sample diagnosis, hematocrit surveillance, and willingness to hold or reduce dose when adverse trends appear. Prescribing TRT to men with normal testosterone because they "feel tired" is not guideline-concordant care.

Injection technique essentials

Patients using a 200 mg/mL vial draw volume with an insulin syringe for subcutaneous injection or a larger syringe for intramuscular delivery. A 100 mg dose equals 0.5 mL; 200 mg equals 1.0 mL. Alcohol-swab the vial top, use sterile technique, inject slowly, and dispose of sharps in an approved container. Vials are multi-dose; once punctured, bacterial contamination risk increases after 28 days in many pharmacy guidelines, so storage and expiration discipline matter.

Stopping TRT

Discontinuation without a plan causes symptomatic crash as the exogenous supply withdraws and the hypothalamic-pituitary-gonadal axis may be slow to recover, especially after prolonged use. Post-cycle recovery protocols (clomiphene, hCG, or enclomiphene) are sometimes employed under medical supervision. Men should not start TRT casually if they intend to stop within months.

CLYR Health offers testosterone cypionate TRT for men with confirmed hypogonadism whose providers determine injectable therapy is appropriate. Treatment requires valid prescription, ongoing lab monitoring, and realistic expectations about fertility, hematocrit, and the chronic nature of replacement therapy.